sRANKL (total) Human ELISA (Osteoprotegerin Ligand)

Catalog number: RD193004200R
Brand: BioVendor
Packing: 96 wells
Price: € 561.00
Expected delivery time: 7 days
Quantity:

Product specifications for - sRANKL (total) Human ELISA (Osteoprotegerin Ligand)

Overview: 
Product group: Assays
Category: ELISA / EIA
Properties: 
Assay Sensitivity: 0,4 pmol/l
Assay Precision: Inter assay: n = 4, CV = 12,0%, Intra assay: n = 8, CV = 9,4%,
Assay Sample Type: serum and plasma (EDTA, citrate, heparin)
Assay Time: The total assay time is about 20 hours
Assay Detection Range: 0,5 - 32 pmol/l
  Research Use Only
UNSPSC: 41116158
Storage instructions: Store the kit at 2-8-¦C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Scientific information: 
Scientific info: sRANKL, receptor activator of nuclear factor (NF)-kappaB ligand (also: osteoprotegerin ligand, OPGL), is a part of the TNF superfamily with high similarity to other members of that protein species. (SwissProt Nr. O14788). Three isoforms are produced by alternate splicing, two type II membrane proteins (ISOFORM 1, 317 AA, and ISOFORM 3, 270 AA), and a secreted molecule (ISOFORM 2, 244 AA). ISOFORM 1 is identical to previously reported RANKL and possesses intracellular, transmembrane, and extracellular domains, ISOFORM 2 does not have the intracellular and transmembrane domains, and ISOFORM 3 does not have the intracellular domain. A soluble form arises by proteolytic processing from membrane isoforms. Although all forms are bioactive, the membrane-bound proteins seem to be the homeostatic forms, while the production of soluble RANKL signals pathological conditions. RANKL, RANK, and osteoprotegerin (OPG) have been identified as the key molecular regulation system for bone remodelling. RANKL is the main stimulatory factor for the formation of mature osteoclasts and is essential for their survival. Therefore, an increase in RANKL expression leads to bone resorption and bone loss. RANKL is produced by osteoblastic lineage cells and activated T lymphocytes. It activates its specific receptor RANK, which is located on osteoclasts and dendritic cells. The effects of RANKL are counteracted by OPG, which is secreted by various tissues and acts as an endogenous soluble receptor antagonist. Imbalances of the RANKL/OPG system have been related to the pathogenesis of Paget s disease, benign and malignant bone tumors, postmenopausal osteoporosis, rheumatoid arthritis, bone metastases and hypercalcemia. Several studies using animal models have shown that restoring the RANKL/OPG balance (e.g. by administering OPG) reduces the severity of these disorders. Indication - Postmenopausal and senile osteoporosis - Diseases with locally increased bone resorption activity - Paget s disease - Periodontal disease - Cardiovascular disease, arterial calcification - Inflammatory diseases - Immunological disorders - Arthritis - Oncology
Swiss prot ID: O14788
Additional information: 
Synonyms: RD193004200R; BioVendor
Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010,12 (1):R29 Read more
Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di Raimondo F, Abraham NG, Asprinio D. Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Miner Metab. 2010 May,28 (3):276-88 Read more
Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016 Oct 6,18 (1):225 Read more
Buondonno I, Rovera G, Sassi F, Rigoni MM, Lomater C, Parisi S, Pellerito R, Isaia GC, D'Amelio P. Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study. PLoS One. 2017 Jun 5,12(6):e0178463. doi: 10.1371/journal.pone.0178463 Read more
Cao H, Wu Y, Li Q, Wu Y, Zhou Q, Røe OD, Chen Y, Wang R, Wang D. Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation. Int J Cardiol. 7 September 2013, Read more
Cao H, Zhou Q, Wu Y, Li Q, Roe OD, Chen Y, Wu Z, Wang D. Preoperative Serum Soluble Receptor Activator of Nuclear Factor-kappaB Ligand and Osteoprotegerin Predict Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Valve Surgery. Ann Thorac Surg. 2013 Sep,96 (3):800-6 Read more
Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, Rosen CF, Gladman DD. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford). 2010 Jul,49 (7):1399-405 Read more
Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol. 2010 Oct,29 (10):1155-61 Read more
Christoforidis A, Economou M, Farmaki E, Tzimouli V, Gombakis N, Athanassiou-Metaxa M. Increased osteoclastic activity as shown by increased sRANK-L/OPG ratio in boys with hemophilia. Ann Hematol. 2010 Aug,89 (8):837-8 Read more
Christoforidis A, Economou M, Papadopoulou E, Kazantzidou E, Farmaki E, Tzimouli V, Tsatra I, Gompakis N, Athanassiou-Metaxa M. Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. Haemophilia. 2011 Jan,17 (1):e217-22 Read more